These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9003820)

  • 21. Gentamicin and tobramycin Kinetics.
    Counts GW; Blair AD; Wagner KF; Turck M
    Clin Pharmacol Ther; 1982 May; 31(5):662-8. PubMed ID: 7075115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurosurgical gram-negative bacillary ventriculitis and meningitis: a retrospective study evaluating the efficacy of intraventricular gentamicin therapy in 31 consecutive cases.
    Tängdén T; Enblad P; Ullberg M; Sjölin J
    Clin Infect Dis; 2011 Jun; 52(11):1310-6. PubMed ID: 21540208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physiologic response of stress and aminoglycoside clearance in critically ill patients.
    Tholl DA; Shikuma LR; Miller TQ; Woodward JM; Cerra FB; Zaske DE
    Crit Care Med; 1993 Feb; 21(2):248-51. PubMed ID: 8428477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum aminoglycoside monitoring by enzyme immunoassay, biological, and fluorescence immunoassay procedures.
    Buchanan AG; Witwicki E; Albritton WL
    Am J Med Technol; 1983 Jun; 49(6):437-41. PubMed ID: 6349357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of target concentration intervention strategy of gentamicin therapy in a malnourished patient population of south India.
    Rajendran SD; Rao YM; Karthikeyan VP
    Indian J Med Res; 2005 Dec; 122(6):511-7. PubMed ID: 16518002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variable pharmacokinetics of extended interval tobramycin or gentamicin among critically ill patients undergoing continuous venovenous hemofiltration.
    Chuk AC; Saeed F; Kousar N; Burrill S; Barns B; Rickrode G; Fu J; Katrych O; Saunders-Hao P; Block C; Lahey T
    Clin Nephrol; 2015 Oct; 84(4):214-21. PubMed ID: 26308080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of children for whom routine monitoring of aminoglycoside serum concentrations is not cost effective.
    Massey KL; Hendeles L; Neims A
    J Pediatr; 1986 Nov; 109(5):897-901. PubMed ID: 3095524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monitoring of a single post-infusion blood sample to estimate the actual peak and trough concentration of tobramycin in critically ill patients.
    Reimann IR; Meier-Hellmann A; Traut T; Reinhart K; Hoffmann A
    Exp Toxicol Pathol; 2003 Jun; 54(5-6):493-8. PubMed ID: 12877363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of aminoglycosides in the treatment of gram-negative infections in surgical patients.
    Crabtree TD; Pelletier SJ; Gleason TG; Pruett TL; Sawyer RG
    Arch Surg; 1999 Dec; 134(12):1293-8; discussion 1298-9. PubMed ID: 10593326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assay of gentamicin and tobramycin in sera of patients by gas-liquid chromatography.
    Mayhew JW; Gorbach SL
    Antimicrob Agents Chemother; 1978 Dec; 14(6):851-55. PubMed ID: 369455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Usage of aminoglycosides and control of therapy].
    Bruun JN; Nordahl H; Eng J
    Tidsskr Nor Laegeforen; 1982 Jan; 102(2):93-5. PubMed ID: 7101252
    [No Abstract]   [Full Text] [Related]  

  • 32. Administration of tobramycin and gentamicin by the intravenous route every 6 hr in patients with normal renal function.
    Setia U; Gross PA
    J Infect Dis; 1976 Aug; 134 Suppl():S125-9. PubMed ID: 972270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parenteral administration of tobramycin for pulmonary exacerbations in cystic fibrosis patients: toxicity, serum levels and efficacy.
    Braccini G; Lori I; Neri AS; Festini F; Pela I; Ciuti R; Boni V; Zavataro L; Braggion C; De Martino M; Taccetti G
    J Chemother; 2009 Feb; 21(1):101-4. PubMed ID: 19297282
    [No Abstract]   [Full Text] [Related]  

  • 34. Prediction of glomerular filtration rate using aminoglycoside clearance in critically ill medical patients.
    Zarowitz BJ; Robert S; Peterson EL
    Ann Pharmacother; 1992 Oct; 26(10):1205-10. PubMed ID: 1421639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective comparison of traditional and pharmacokinetic aminoglycoside dosing methods.
    Franson TR; Quebbeman EJ; Whipple J; Thomson R; Bubrick J; Rosenberger SL; Ausman RK
    Crit Care Med; 1988 Sep; 16(9):840-3. PubMed ID: 3402229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of a microcomputer program (OPT) for parameter optimisation in clinical pharmacokinetics: gentamicin and tobramycin.
    Zantvoort FA; Wagenvoort JH; Derkx FH; Michel MF
    Br J Clin Pharmacol; 1987 Oct; 24(4):511-8. PubMed ID: 3689631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of a 3 mg/kg body weight loading dose of gentamicin or tobramycin in critically ill patients.
    Chelluri L; Warren J; Jastremski MS
    Chest; 1989 Jun; 95(6):1295-7. PubMed ID: 2721269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia.
    Moore RD; Smith CR; Lietman PS
    J Infect Dis; 1984 Mar; 149(3):443-8. PubMed ID: 6715900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors affecting gentamicin pharmacokinetics in septic patients.
    Tang GJ; Tang JJ; Lin BS; Kong CW; Lee TY
    Acta Anaesthesiol Scand; 1999 Aug; 43(7):726-30. PubMed ID: 10456812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients.
    Mahmoudi L; Mohammadpour AH; Ahmadi A; Niknam R; Mojtahedzadeh M
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17(3):285-91. PubMed ID: 23426530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.